Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%

Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business

Syngene Q2 FY23 PAT up 11% to Rs. 102 Cr

Revenue from operations up 26% to Rs. 768 crores

RPG Life Sciences Q2 FY23 revenue up 20%; PBT up 21%

In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Sanofi India Q2 CY2022 PAT drops 49.5% to Rs. 120.4 Cr

Sanofi India has reported total income of Rs. 715 crores during the period ended June 30, 2022.

Aster DM Healthcare PAT at Rs 107 cr. in Q2FY22

Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021

Natco Pharma PAT at Rs 65.1 cr. in Q2FY22

Natco Pharma has reported consolidated financial results for the period ended September 30, 2021

Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22

Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.

J.B Chemicals & Pharmaceuticals PAT at Rs 98 cr. in Q2FY22

J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021

Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22

The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.